Send to

Choose Destination
Cancer Res. 2018 Sep 15;78(18):5243-5258. doi: 10.1158/0008-5472.CAN-18-0413. Epub 2018 Jul 16.

IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer.

Author information

Baylor Institute for Immunology Research, Baylor Research Institute, Dallas, Texas.
The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.
Department of Biomedical Studies, Baylor University, Waco, Texas.
The Center for Cancer and Blood Disorders, Fort Worth, Texas.
Baylor University Medical Center, Sammons Cancer Center, Dallas, Texas.
Baylor University Medical Center, Charles A. Sammons Cancer Center, Texas Oncology, Dallas, Texas.
Baylor Institute for Immunology Research, Baylor Research Institute, Dallas, Texas.
Contributed equally


Inflammation affects tumor immune surveillance and resistance to therapy. Here, we show that production of IL1β in primary breast cancer tumors is linked with advanced disease and originates from tumor-infiltrating CD11c+ myeloid cells. IL1β production is triggered by cancer cell membrane-derived TGFβ. Neutralizing TGFβ or IL1 receptor prevents breast cancer progression in humanized mouse model. Patients with metastatic HER2- breast cancer display a transcriptional signature of inflammation in the blood leukocytes, which is attenuated after IL1 blockade. When present in primary breast cancer tumors, this signature discriminates patients with poor clinical outcomes in two independent public datasets (TCGA and METABRIC).Significance: IL1β orchestrates tumor-promoting inflammation in breast cancer and can be targeted in patients using an IL1 receptor antagonist. Cancer Res; 78(18); 5243-58. ©2018 AACRSee related commentary by Dinarello, p. 5200.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center